Cancer patients at Memorial Hermann have access to appropriate clinical trials through their doctors. Any patient participating in a clinical trial at Memorial Hermann receives the standard-of-care treatment, in addition to the new therapy under consideration. When a proven standard-of-care treatment seems to provide insufficient attack against a patient’s cancer, qualified patients can be enrolled in ongoing community-based trials.
Current clinical trials and research projects are available for the following cancers:
BONE
For newly diagnosed high-risk Ewing’s Sarcoma patients
Study ID HSC-GEN-02-007: Randomized Phase 2 study of Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) with or without IMMTher for newly diagnosed high-risk Ewing’s Sarcoma
Principal investigator: Eugenie Kleinerman, MD
Learn more.
BRAIN
Molecular and genetic epidemiology of gliomas
Study ID HSC-GEN-06-0336
Principal investigator: Melissa Bondy, MD
Learn more.
Meningioma: Risk factors and quality of life
Study ID HSC-MH-07-0102
Principal investigator: Melissa Bondy, MD
Learn more.
BREAST
For patients with stage 0, I, II breast cancer
Study ID HSC-MS-05-0536: Randomized phase 3 study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, II, breast cancer
Principal investigator: Emily Robinson, MD
Learn more.
For patients with HER2-negative, metastatic or locally recurrent breast cancer
Protocol 20060341: Randomized, 4-arm placebo-controlled Phase 2 Trial of Paclitaxel in combination with bevacizumab and AMG386 as first lien therapy in subjects with HER2-negative, metastatic or locally recurrent breast cancer
Sponsor: Amgen
Principal investigator: Arvind Bhandari, MD
For more information: Contact Julia Powers, RN, MSN, CCRP, at 713-456-4011 or Kristin Chandler, RN, CCRP, at 713-456-4073.
CERVICAL
For patients with recurrent or persistent carcinoma of the cervix
Study ID HSC-MS-03-220: Randomized Phase 3 trial of Paclitaxel plus Cisplatin versus Vinorelbine plus Cisplatin versus Vinorelbine plus Cisplatin versus Gemcitabine plus Cisplatin versus Topotecan plus Cisplatin in stage IVB recurrent or persistent carcinoma of the cervix
Principal investigator: Lois Ramondetta, MD
Learn more.
GYNECOLOGICAL
Gynecological Neoplasms
Study ID HSC-MS-07-0112: Morphologic, immunohistochemical and molecular analysis of gynecological nepolasms
Principal investigator: Xiuzhen Duan, MD
Learn more.
LIVER
For patients with liver tumors
Study ID HSC-MS-04-231: Codified database for the ongoing evaluation of the use of SIRspheres for treatment of liver tumors
Principal investigator: Alan Cohen, MD
Learn more.
LUNG
Patients with non-small cell lung cancer who are receiving chemotherapy regimen of Gemcitabine and Platinum and experiencing a severe drop in their platelet counts
Protocol 20050154: Phase 2 randomized double-blind placebo-controlled dose and schedule finding trial to evaluate the safety and efficacy of AMG531 for treatment of chemotherapy-induced thrombocytopenia in subjects with advanced non-small cell lung cancer already receiving Gemcitabine and Platinum
Sponsor: Amgen
Principal investigator: William Velasquez, MD
Sub-investigator: Charles Conlon, MD
For more information: Contact Julia Powers, RN, MSN, CCRP, at 713-456-4011, or Kristin Chandler, RN, CCRP, at 713-456-4073.
LYMPHOMA
For patients with lymphoma who are experiencing a severe drop in their platelet counts following a cycle of chemotherapy
Protocol 20050144: Open label dose and schedule finding trial to evaluate the safety and efficacy of AMG531 for treatment of severe thrombocytopenia due to multi-cycle chemotherapy in adult subjects with lymphoma
Sponsor: Amgen
Principal investigator: William Velasquez, MD
Sub-investigator: Charles Conlon, MD
For more information: Contact Julia Powers, RN, MSN, CCRP, at 713-456-4011, or Kristin Chandler, RN, CCRP, at 713-456-4073.
For patients with relapsed or refractory, CD22-positive, follicular B-cell Non-Hodgkin’s lymphoma
Protocol 3129K4-3301-WW: An open-label, randomized, phase 3 study of Inotuzumab Ozogamicin (CMC-544) administered in combination with Rituximab compared to a defined investigator’s choice therapy in subjects with relapsed or refractory, CD22-positive, follicular B-cell Non-Hodgkin’s lymphoma
Sponsor: Wyeth Pharmaceuticals
Principal investigator: William Velasquez, MD
Sub-investigator: Charles Conlon, MD
For more information: Contact Julia Powers, RN, MSN, CCRP, at 713-456-4011, or Kristin Chandler, RN, CCRP, at 713-456-4073.
OVARIAN
For epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer patients
Study ID HSC-MH-05-001: Phase 2 study evaluating the utility of Letrozole in the treatment of recurrent, Platinum and Taxan resistant, estrogen receptor (ER) positive, epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer patients
Principal investigator: Lois Ramondetta, MD
Learn more.
PANCREATIC
For patients with locally invasive pancreatic cancer
Study ID HSC-MS-05-0022: Randomized phase 2 clinical trial of optimally scheduled chemo-biotherapy with or without fever-range whole body thermal-therapy (FR-WB-TT) in patients with locally invasive pancreas cancer
Principal investigator: Joan Bull, MD
Learn more.
PEDIATRIC
A retrospective analysis of pediatric melanoma cases in Texas
Study ID HSC-MS-07-0638
Principal investigator: Adelaide Hebert, MD
Learn more.
PROSTATE
Patients who have just been diagnosed with high-risk or locally advanced prostate cancer and have not yet received treatment
Protocol 05-043: Docetaxel (Taxotere) plus six-month androgen suppression and radiation therapy vs. six-month androgen suppression or radiation therapy for patients with high-risk localized or locally advanced prostate cancer: a randomized controlled trial
Sponsor: Dana-Farber Cancer Institute
Principal investigator: William Velasquez, MD
Sub-investigator: Charles Conlon, MD & John Van, MD
For more information: Contact Julia Powers, RN, MSN, CCRP, at 713-456-4011, or Kristin Chandler, RN, CCRP, at 713-456-4073.
Patients who have been diagnosed with prostate cancer and just had a radical prostatectomy
Protocol 3501: Multicenter, open-label, randomized Phase III trail campaign immediate adjuvant hormonal therapy (Eligard® – leuprolide acetate in combination with taxotere (docetaxel) administered every three weeks vs. hormonal therapy alone vs. deferred therapy followed by the same therapeutic options in patients with prostate cancer at high risk relapse after radical prostatectomy
Principal investigator: Sam Axelrad, MD
For more information: Contact Julia Powers, RN, MSN, CCRP, at 713-456-4011, or Kristin Chandler, RN, CCRP, at 713-456-4073.
Patients who have prostate cancer, have received treatment and now are experiencing rising PSAs
Protocol 20050147: Randomized double-blind, placebo-controlled, multi-center Phase III study of Denosumab on prolonging bone metastasis-free survival in men with hormone refractory prostate cancer
Sponsor: Amgen
Principal investigator: Sam Axelrad, MD
For more information: Contact Julia Powers, RN, MSN, CCRP, at 713-456-4011, or Kristin Chandler, RN, CCRP, at 713-456-4073.
Patients with hormone refractory metastatic prostate cancer previously treated with a Taxotere containing regimen
Protocol EFC6193 TROPIC: A randomized, open-label multi-center study of XRP6258 at 25mg/m² in combination with Prednisone every 3 weeks compared to Mitoxantrone in combination with Prednisone for the treatment of hormone refractory metastatic prostate cancer previously treated with a Taxotere containing regimen
Sponsor: Sanofi-Aventis
Principal investigator: Sam Axelrad, MD
Sub-investigator: Charles Conlon, MD
For more information: Contact Julia Powers, RN, MSN, CCRP, at 713-456-4011, or Kristin Chandler, RN, CCRP, at 713-456-4073.
Patients with prostate cancer who have failed first-line Androgen Deprivation Therapy (assessed by rising PSA)
Protocol AVO108943: A randomized double blind parallel group study comparing Casodex 50mg plus placebo to Casodex 50mg plus dutasteride 3.5mg administered for 18 months to men with prostate cancer who have failed first-line Androgen Deprivation Therapy (assessed by rising PSA) followed by a two-year extension phase
Sponsor: GlaxoSmithKline
Principal investigator: Sam Axelrad, MD
For more information: Contact Julia Powers, RN, MSN, CCRP, at 713-456-4011, or Kristin Chandler, RN, CCRP, at 713-456-4073.
Patients with metastatic androgen-independent prostate cancer
Protocol EFC6546 Venice: AVE0005 (VEGF Trap) A multi-center, randomized, double-blind study comparing the efficacy and safety of VEGF trap versus placebo administered every 3 weeks in patients treated with Docetaxel/Prednisone for metastatic androgen-independent prostate cancer
Sponsor: Sanofi-Aventis
Principal investigator: Sam Axelrad, MD
For more information: Contact Julia Powers, RN, MSN, CCRP, at 713-456-4011, or Kristin Chandler, RN, CCRP, at 713-456-4073.
Clinically asymptomatic prostate cancer patients with a rising PSA following definitive local therapy
Protocol XRP6976J/3503: A randomized, open label multi-center, Phase 3, 2-arm study of androgen deprivation with Leuprolide, +/- Docetaxel for clinically asymptomatic prostate cancer subjects with a rising PSA following definitive local therapy
Sponsor: Sanofi-Aventis
Principal investigator: Sam Axelrad, MD
For more information: Contact Julia Powers, RN, MSN, CCRP, at 713-456-4011, or Kristin Chandler, RN, CCRP, at 713-456-4073.
Patients with prostate cancer at high risk of relapse after radical prostatectomy
Study ID HSC-GEN-07-0353: A multicenter, open-label randomized Phase Iii trial comparing immediated adjuvant hormonal therapy (Eligard® - Leuprolide Acetate) in combination with Taxotere® (Docetaxel) administered every three weeks versus hormonal therapy alone versus deferree therapy followed by the same therapeutic options in patients with prostate cancer at high risk of repalse after radical prostatectomy (Xrp6976j/3501 Taxotere® (Docetaxel)
Principal investigator: Kevin Slawin, MD
Prostate cancer screening program
Study ID HSC-GEN-07-0461
Principal investigator: Kevin Slawin, MD
UROLOGICAL
Women with overactive bladder, including urinary incontinence
Protocol DRI6271: A placebo controlled randomized, 12-week, dose-ranging, double-blind study versus placebo using tolterodine as a study calibrator, to evaluate efficacy and safety of SSR240600C in women with overactive bladder including urge urinary incontinence
Sponsor: Sanofi-Aventis
Principal investigator: Sam Axelrad, MD
Sub-investigator: Kevin Nickell, MD
For more information: Contact Julia Powers, RN, MSN, CCRP, at 713-456-4011 or Kristin Chandler, RN, CCRP, at 713-456-4073.
Patients with locally advanced/metastatic urothelial tract or bladder cancer
Protocol EFC6668: Randomized study of Larotaxel + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the first line treatment of locally advanced/metastatic urothelial tract or bladder cancer
Sponsor: Sanofi-Aventis
Principal investigator: Sam Axelrad, MD
Sub-investigator: Charles Conlon, MD
For more information: Contact Julia Powers, RN, MSN, CCRP, at 713-456-4011 or Kristin Chandler, RN, CCRP, at 713-456-4073.
UTERINE
For low-risk Gestational Trophoblastic Neoplasia (abnormal cells inside the uterus)
Study ID HSC-GEN-04-009: Randomized Phase 3 trial of weekly parenteral Methotrexate versus “pulsed” Dactinomycin as primary management for low-risk gestational trophoblastic neoplasia
Principal investigator: Lois Ramondetta, MD
Learn more.
MULTIPLE CANCER TYPES
Dendritic cell vaccine
HSC-MS-07-0484: Pilot study to assess the product manufacturing, characteristics and testing of BP-GMAX-CD1, an adenoviral vector-modified dendritic cell vaccine, using leukapheresis product from healthy blood donors.
Principal investigator: Orieji Illoh, MD
Learn more.
Compassion Use Lenalidomide (Revlimid)
Principal investigator: Joel Abramowitz, MD
Learn more.
Ambulatory Cancer Pain Management: A descriptive study
Study ID HSC-SN-04-038
Principal investigator: Kristin Ownby
Learn more.
For patients with advanced malignancy
Study ID HSC-MS-01-111
Phase 2 study of mild whole body hyperthermia combined with 5-Fluorouacil/Interferon-a/Liposomal Doxorubicin in patients with advanced malignancy
Principal investigator: Joan Bull, MD
Learn more.
For patients with advanced malignancy
Study ID HSC-MS-02-117: Phase 2 clinical trail of timing/schedule optimized combined-modality regimen of Cisplatin + Metronomic low-dose Interon-a (IFN-a) followed by Gemcitabine HCI (Gemzar) in combination with mil, fever-range whole body hyperthermia in patients with advanced malignancy
Principal investigator: Joan Bull, MD
Learn more.
For patients with advanced malignancy
Study ID HSC-MS-04-259: Phase 2 clinical trial of Cisplatin (Platinorl) followed by Gemcitabien HCI (Gemzar) in combination with mild, fever-range, whole body thermal-therapy (FR-WB-TT) of 40° C (104° F) in patients with advanced malignancies
Principal investigator: Joan Bull, MD
Learn more.
Research into the use of thermal therapy, or heat treatment, technically known as hyperthermia for cancer is being conducted at The University of Texas Houston Medical School and its teaching hospital, Memorial Hermann-Texas Medical Center. Thermal therapy treatment has evolved from age-old observations that cancer sufferers who sustained prolonged high fevers due to concomitant infectious disease often witnessed tumor regression or cures.
With modern science and technology, it has become possible to mimic fever by inducing controlled heating of the whole body or individual tissues. The focus of both our laboratory research and clinical research is the use of systemic heating or whole body thermal therapy to induce a fever-like state in order to treat metastatic cancer. Our goal is to rapidly translate the results of laboratory research into clinical protocols.
Learn more.
|
